LONDON May 6 Britain needs assurances from U.S.
drugs company Pfizer that it will maintain research
activity in Britain beyond the short term if it takes over
AstraZeneca, the Confederation of British Industry said
"The most important issue for British business with this
proposed takeover is the strength of the UK scientific research
base of which pharma is a critical part," CBI director-general
John Cridland said in a statement.
"If a proposed takeover proceeds, it would be vital for the
UK Government to receive assurances about the maintenance of
research activity in the UK which sustain over time," he added.
(Reporting by David Milliken)